metastatic Endometrial carcinoma (DBCOND0021883)

Identifiers

Synonyms

Carcinoma endometrial metastatic / Metastatic Endometrial Carcinoma / Endometrial carcinoma stage IV / Endometrial carcinoma metastatic / Endometrial neoplasm malignant stage IV / Ca endometrium stage IV / Ca endometrium metastatic / Cancer of endometrium stage IV / Cancer of endometrium metastatic / Endometrial cancer metastatic / Endometrial cancer stage IV / Endometrial neoplasm malignant metastatic

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Medroxyprogesterone acetate	A progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty.	Progesterone receptortarget Estrogen receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A1enzyme Albumincarrier ATP-dependent translocase ABCB1target GABA(A) Receptortarget ATP-dependent translocase ABCB1transporter
Megestrol acetate	A progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.	Progesterone receptortarget Glucocorticoid receptortarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05691504	Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Cobimetinib Pelcitoclax	treatment	1	recruiting
NCT06264921	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors	No drug interventions	treatment	1	recruiting
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Albumin human Atezolizumab Cabozantinib Paclitaxel	treatment	1	recruiting
NCT06349642	Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform	No drug interventions	Not Available	Not Available	recruiting
NCT06586957	A Study with NKT3964 for Adults with Advanced/Metastatic Solid Tumors	No drug interventions	treatment	1	not_yet_recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT03508570	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT03367741	Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer	Cabozantinib Nivolumab	treatment	2	active_not_recruiting
NCT03120624	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	Human interferon beta Ruxolitinib Sodium iodide Technetium Tc-99m pertechnetate	treatment	1	active_not_recruiting